Search PubMed⌕ Search

Biomedical subjects

J Ishigami

Publications and source records attributed to J Ishigami.

At least 73 records · Page 4Linked to original sources
PubMed1981

A fundamental study of regional chemotherapy given by intraarterial infusion with concomitant hemodialysis and hemoperfusion.

In the intraarterial infusion of anticancer drugs, the majority of systemic side effects are caused by the systemic circulation of the infused drug. If the extraregional infusate could be removed by hemodialysis (HD) or direct hemoperfusion (DHP), side effects in the intraarterial infusion therapies could be mitigated and regional administration of anticancer drugs in large doses would than be possible. To substantiate this postulate, the authors carried out in vivo experiments using mongrel dogs, and obtained the results evidencing removal of extra regional anticancer drugs by HD and DHP. The maximum mitomycin C clearance of HD was 35.7 ml per min, whereas that of DHP was 119.7 ml per min. The results show the usefulness of concomitant use of HD or DHP in the intraarterial infusion of anticancer drugs via internal iliac artery in the treatment of cancer of the urinary bladder.

Animals↗
PubMed1977

Clinical evaluation of pivmecillinam in acute simple cystitis: a comparative study with amoxycillin by a randomized double-blind technique.

The comparative efficacy of pivmecillinam and amoxycillin in 243 patients with acute simple cystitis was determined in a randomized double-blind trial. Pivmecillinam was found to be significantly more effective on both clinical and bacteriological grounds. The superiority of pivmecillinam was primarily due to its efficacy in infections due to ampicillin resistant Escherichia coli. Fewer side effects were reported in patients who received pivmecillinam.

Acute Disease↗
PubMed1977

Clinical evaluation of pivmecillinam in intractable urinary-tract infections with complications. A comparative study with amoxicillin by a randomized double-blind technique.

A comparative study was made by the double-blind technique in order to make clear the usefulness of pivmecillinam in the treatment of intractable complicated urinary-tract infections using amoxicillin as a reference drug. Pivmecillinam was given in dosage of 400 mg (potency) per day which was one-fifth the dose of amoxicillin 2,000 mg (potency) per day. In global judgement, pivmecillinam was found superior to amoxicillin. It showed a "significant" superiority over amoxicillin for the treatment of, among others, the urinary-tract infections after prostatectomy, which are intractable diseases. When evaluated by symptoms, pivmecillinam improved bacteriuria "significantly" better than amoxicillin. When seen by causative organisms, the pivmecillinam treatment was "significantly" superior to the amoxicillin treatment against E. coli infections. Pivmecillinam was active against amoxicillin-resistant E. coli. Incidence of adverse reactions was less frequent with pivmecillinam than with amoxicillin. These results indicate that pivmecillinam is a drug of high usefulness for the treatment of intractable complicated urinary-tract infections when evaluated using amoxicillin as a reference drug.

Adult↗
PubMed1976

[Comparative results of cephacetrile with cefazolin in complicated urinary tract infections by means of double-blind trials (author's transl)].

In order to elucidate the usefulness of cephacetrile (CEC), comparative trials with cefazolin (CEZ) were carried out in the patients with complicated infections of the urinary tract, and the following results were obtained: 1. There were no statistically significant differences or tendencies observed between the groups given CEC and CEZ in either of the global effects, bacteriological effects, rate of superinfection, relapse, relapse with bacterial alternation, drug usefulness, rate of improvements in symptoms and findings in all the cases. 2. According to a result of stratified analyses, there were statistically significant differences observed, showing more inferior results of CEC than CEZ in either stratum of "below 50" in the age, "acute" in the disease phase, "infections of the upper urinary tract" in the disease pattern, and "E. coli including mixed infections with gram-positive organisms" in the pathogenic strains. However, it should be taken into consideration that certain background factors influence greatly in the effects and there were some problems on deviated backgrounds in these strata. On the other hand, CEC displayed better bacteriological effects than those of CEZ in higher stratum of "chronic" in the disease phase and "Klebsiella, Proteus, Citrobacter, Enterobacter including mixed infections" in the pathogenic strains, and statistically significant differences were not observed. 3. In consequence of bacteriological studies, CEC showed stronger resistance than CEZ against beta-lactamase produced in all the strains of gram-negative bacilli. Particularly there were significant differences or tendencies observed in those of Proteus, Cirtobacter, and Enterobacter, and at the same time there were great differences in the activity of beta-lactamase between CEC and CEZ as the substrate. 4. In correlation of the MIC and effects, CEC showed weaker actions than CEZ against susceptible organisms, but slightly stronger actions against moderately or highly resistant strains. A study of the relationship between the MIC of pathogenic strains, beta-lactamase, and bacteriological effects, showed possibilities that even the high activity of beta-lactamase results in remarkable effects in susceptible strains and the drugs with stronger resistance against beta-lactamase given better results in moderately or highly resistant organisms. 5. The incidence rate of adverse reactions was 2 out of 51 cases in the CEC group (3.9%) and 3 out of 50 cases in the CEZ group (6.0%), showing no significant difference, and those symptoms were similar. In conclusion, when the usefulness of CEC in complicated infections of the urinary tract is compared with that of CEZ, the former is said to be equal to the latter without significant difference as a whole...

Adult↗